OncoSec Medical Inc. (OTCQB:ONCS), a company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumors, has announced it will be presenting at the Cancer
Vaccines and Gene Therapy Meeting at The Desmond Malvern Hotel in
Philadelphia, Pennsylvania.
Dr. Richard Heller, Professor at Old Dominion University, will be
presenting pre-clinical data on the use of electroporation to deliver
plasmid IL-12 in solid tumors in a presentation titled “Gene
Electrotransfer as an Effective Delivery Tool.” This presentation
will take place on Thursday, October 3 at 3:30 p.m. EST.
Dr. Adil Daud, principal investigator and co-director of melanoma
research at the University of California San Francisco School of
Medicine, will be presenting an update to OncoSec’s Phase II melanoma
immune response data, which will include IL-12 expression findings in a
presentation titled “Gene Electrotransfer in Solid Tumors.” This
presentation will take place on Friday, October 4 at 1:00 p.m. EST.
About the Cancer Vaccines and Gene Therapy Meeting
The Cancer Vaccines and Gene Therapy Meeting will bring together
important leaders to present and discuss the latest approaches and
technologies used to develop promising anti-cancer therapeutics.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumors. ImmunoPulse and NeoPulse therapies address an
unmet medical need and represent a potential solution for less invasive
and less expensive therapies that are able to minimize detrimental
effects resulting from currently available cancer treatments such as
surgery, systemic chemotherapy or immunotherapy, and other treatment
alternatives. OncoSec Medical's core technology is based upon its
proprietary use of an electroporation platform to enhance the delivery
and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse)
or chemotherapeutic agent (NeoPulse). Treatment of various solid
cancers using these targeted anti-cancer agents has
demonstrated selective destruction of cancerous cells while potentially
sparing healthy normal tissues during early and late stage clinical
trials. OncoSec's clinical programs include three Phase II clinical
trials for ImmunoPulse targeting lethal skin cancers. More information
is available at http://www.oncosec.com/.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such "forward-looking statements." Forward-looking statements
are based on management's current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical's filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
Copyright Business Wire 2013